Company Overview - ORIC is participating in Citi's 2026 Virtual Oncology Leadership Summit, with CEO Jacob Chacko and CFO Dominic Piscitelli present for discussions [1]. - The session aims to provide insights into ORIC's operations, particularly focusing on their prostate cancer program [2]. Key Discussion Points - The discussion will begin with a high-level overview of ORIC, followed by specific questions regarding their prostate cancer initiatives [2].

Summary of ORIC Pharmaceuticals Conference Call Company Overview - ORIC Pharmaceuticals is a clinical-stage oncology company focused on overcoming resistance in cancer, particularly in prostate, lung, and breast cancer [2][3] Key Programs - **ORIC-944**: An allosteric PRC2 inhibitor for prostate cancer, expected to start a Phase III study in the first half of 2026 [2][7] - **Enozertinib (ORIC-114)**: A selective brain-penetrant EGFR inhibitor targeting exon 20 and PACC mutations, with updates expected in the second half of 2026 [3][34] Competitive Landscape - Pfizer's **Mevrometostat** showed a PFS of 14.3 months in prostate cancer, which ORIC aims to match or exceed with their own data [5][6] - ORIC's early data showed a PSA 50 response of 40% compared to Pfizer's 34%, indicating a potentially better efficacy profile [6][10] Safety and Efficacy - ORIC believes that safety is a significant differentiator in prostate cancer treatments, with their program showing fewer adverse events compared to Pfizer's [10][13] - The company does not believe it needs to be differentiated in efficacy due to the large market and unmet needs in prostate cancer [11][12] Market Opportunity - The metastatic CRPC market is estimated to have 30,000-40,000 patients annually in the US, with a significant portion having prior exposure to AR inhibitors [25][26] - The potential market opportunity for ORIC's treatments in the post-abi setting is estimated at $3.5 billion [28] Financial Position - ORIC raised $244 million in mid-2025, providing a cash runway into the second half of 2028, which covers the costs of the first Phase III study [24][46] - The company is well-capitalized and does not require a corporate partner to initiate the first Phase III study [22][23] Future Plans - An update on dose optimization data for ORIC-944 is expected in Q1 2026, with a focus on PSA responses and safety [15][17] - ORIC plans to evaluate which AR inhibitor (apalutamide or darolutamide) to use in the Phase III study based on data from the Q1 update [19][20] Enozertinib Development - ORIC plans to continue investing in enozertinib, with a focus on CNS activity, which is a significant unmet need in lung cancer [35][36] - The company aims to differentiate itself in the EGFR market, which is competitive and requires best-in-class inhibitors [39][40] Conclusion - ORIC Pharmaceuticals is positioned to capitalize on significant market opportunities in oncology, with a strong focus on safety and efficacy in its drug development programs. The company is financially stable and prepared to advance its clinical trials without immediate need for external partnerships.

Core Insights - ORIC Pharmaceuticals, Inc. is focusing on developing best-in-class small molecule inhibitors, differentiating itself from the majority of the biotech industry that is centered on new modalities [1] Group 1: Company Focus - ORIC Pharmaceuticals is pursuing a unique strategy in the biotech sector by concentrating on small molecule inhibitors rather than the more common focus on new modalities [1] Group 2: Analyst Perspective - The analysis emphasizes a strong inclination towards high-growth companies and sectors that are expected to experience exponential expansion, highlighting the importance of innovation for substantial returns [1]

Core Viewpoint - ORIC Pharmaceuticals is focused on overcoming resistance in cancer, with a mission to develop innovative therapies for oncology patients [3]. Company Overview - ORIC has assembled a team of experienced drug hunters and developers who have previously worked at leading oncology companies, contributing to the development of successful and commercialized products [3]. Pipeline Assets - The company has two late-stage pipeline assets: rinzimetostat, targeting prostate cancer, and enozertinib, aimed at lung cancer [4]. - Significant data on both drugs has been presented in previous years, particularly in 2025, with more data expected to be shared in the current year [4].

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Summary of ORIC Pharmaceuticals FY Conference Call Company Overview - **Company Name**: ORIC Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Oncology - **Mission**: Overcoming Resistance in Cancer, focusing on developing therapies for cancer patients [2][3] Key Pipeline Assets - **Rinsey-Metastat**: A PRC2 inhibitor for prostate cancer, expected to have a phase three data readout in the second half of 2027 [3][11] - **Enosertinib**: A brain-penetrant TKI for lung cancer, targeting EGFR exon 20 and PAC mutations, with a phase three dose selected [5][35] Financial Position - **Cash Runway**: Well-funded with cash runway extending into the second half of 2028, allowing for continued development of both pipeline assets [3][11] Clinical Development Highlights Rinsey-Metastat - **Combination Studies**: Being developed in combination with apalutamide (J&J) and daralutamide (Bayer) [4][7] - **Safety Profile**: Demonstrated a differentiated safety profile compared to competitors, which is crucial for long-term dosing [8][29] - **Efficacy Data**: - Confirmed PSA response rates of 40% for PSA 50 and 20% for PSA 90, significantly higher than expected rates for AR inhibitors alone [24] - ctDNA clearance rate of 59%, indicating strong activity [26][27] Enosertinib - **CNS Activity**: Achieved a 100% intracranial objective response rate (ORR) in patients with measurable disease, highlighting its potential in treating CNS metastases [10][33] - **Patient Enrollment**: Allowed patients with active untreated CNS metastases, which is uncommon in competitor studies [34] Competitive Landscape - **Main Competitor**: Pfizer's mevrometostat, which has shown promising results but comes with higher toxicity [6][28] - **Market Opportunity**: The prostate cancer market is substantial, with AR inhibitors generating $11 billion in global revenue [16][17] Future Milestones - **Phase 3 Studies**: Expected to initiate one or two phase 3 studies within the year for both Rinsey-Metastat and Enosertinib [46] - **Data Releases**: Anticipated data from dose optimization studies in Q1 2026, focusing on efficacy and safety [50] Additional Insights - **Long-term Durability**: The combination of Rinsey-Metastat with AR inhibitors aims to extend the durability of treatment, addressing a significant unmet need in prostate cancer [17][19] - **Broader Applications**: Potential future development of PRC2 inhibitors in other cancers, including lung and breast cancer [30] Conclusion - ORIC Pharmaceuticals is positioned to make significant advancements in oncology with its innovative pipeline, particularly in addressing unmet needs in prostate and lung cancer, while maintaining a strong financial position to support its development efforts [46]

Core Insights - ORIC Pharmaceuticals announced promising Phase 1b data for rinzimetostat and enozertinib, indicating potential best-in-class efficacy and safety in treating metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) respectively [1][2][4] - The company raised $244 million from healthcare specialist funds, providing a cash runway into the second half of 2028, which supports ongoing clinical trials and potential commercialization efforts [1][8] - Multiple clinical data readouts for rinzimetostat and enozertinib are expected in 2026, ahead of the initiation of several registrational trials [1][2] Rinzimetostat Highlights - Rinzimetostat is a potent and selective allosteric inhibitor of PRC2, showing significant PSA responses and ctDNA reductions in mCRPC patients [3][5] - In combination with darolutamide and apalutamide, 55% of patients achieved a PSA50 response, and 20% achieved a PSA90 response, with rapid ctDNA responses observed [5] - The safety profile of rinzimetostat in combination regimens is favorable, with most treatment-related adverse events being Grade 1 or 2 [5] Enozertinib Highlights - Enozertinib is a brain-penetrant inhibitor targeting EGFR exon 20 and EGFR PACC mutations, demonstrating competitive systemic and intracranial activity in NSCLC patients [4][11] - The Phase 1b trial reported a 67% overall response rate (ORR) in EGFR exon 20 and an 80% ORR in EGFR PACC, with 100% intracranial ORR in patients with measurable CNS disease [11] - A clinical trial collaboration with Johnson & Johnson was announced to evaluate enozertinib in combination with amivantamab for first-line treatment of NSCLC patients [11] Financial Position - As of September 30, 2025, ORIC's cash, cash equivalents, and investments totaled $413 million, expected to fund operations into the second half of 2028 [8] - The company has strengthened its cash position through a private placement and an at-the-market program throughout 2025 [11] Upcoming Milestones - For rinzimetostat, the company plans to report combination dose optimization data in Q1 2026 and initiate the first global Phase 3 trial in mCRPC in the first half of 2026 [11] - For enozertinib, monotherapy data for EGFR exon 20 and PACC is anticipated in the second half of 2026 [11]

Company Overview - ORIC Pharmaceuticals, Inc. is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance [3] - The company is headquartered in South San Francisco and San Diego, California [3] Product Candidates - ORIC's clinical stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) targeting prostate cancer [3] - Another candidate is enozertinib (ORIC-114), a brain-penetrant inhibitor targeting EGFR exon 20 and atypical mutations, being developed for multiple genetically defined cancers [3] Upcoming Presentation - Jacob M. Chacko, M.D., the CEO of ORIC, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT [1] - A live webcast of the presentation will be available on the company's investor section of the website, with a replay accessible for 90 days post-event [2]

Summary of Key Points from Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology sector, specifically highlighting companies with significant potential for growth and upcoming catalysts in 2026. Key Companies and Their Outlook 1. **Dianthus Therapeutics, Inc. (DNTH)** - Market Cap: $1.82 billion - Price Target: $66 - Key catalysts include: - CIDP Phase III interim analysis in Q2 2026 - Initiation of gMG Phase III study in mid-2026 - Phase II MMN topline data in 2H26 - Potential for significant upside based on peak revenue estimates of ~$2 billion across neuromuscular diseases [19][20][24] 2. **Taysha Gene Therapies, Inc. (TSHA)** - Market Cap: $1.50 billion - Price Target: $11 - Focus on pivotal study for TSHA-102 in Rett syndrome with potential for a 6-month interim readout by YE26/1Q27 [26][27] 3. **Tyra Biosciences (TYRA)** - Market Cap: $1.36 billion - Price Target: $32 - Major catalysts include: - Phase III data for achondroplasia in early 2026 - Initial data for IR-NMIBC in 1H26 - Potential to disrupt the market with oral FGFR3 inhibitors [31][35] 4. **Tango Therapeutics, Inc. (TNGX)** - Market Cap: $1.15 billion - Price Target: $14 - Expected to show de-risking data for vopimetostat in combination with RVMD's RAS inhibitors in 2026 [37][40] 5. **ORIC Pharmaceuticals (ORIC)** - Market Cap: $783 million - Price Target: $23 - Key catalysts include dose-optimization data for prostate cancer and validating data from PFE's MEVPRO-1 trial [42][48] 6. **Solid Biosciences (SLDB)** - Market Cap: $463 million - Price Target: $15 - Focus on DMD program with key regulatory feedback expected in 1H26 [49][53] Major Catalysts and Events - **Upcoming Catalysts:** - RARE and MREO Phase III ORBIT final analysis expected in Dec'25/Jan'26 with potential stock movements of +100%/-30% [2] - ALNY, CRSP, and others expected to provide revenue guidance and business plans early in 2026 [1] - Regulatory events including FDA's Rare Disease Day on 2/23/26 [12] - **Drug Launches:** - Expected launches in 2026 include drugs from ALNY, ARWR, KALV, and others targeting various conditions [3] Financial Updates - **Price Target Changes:** - ARWR raised from $67 to $90 - KOD raised from $24 to $39 [6][10] Market Dynamics - **Pricing Stability:** - 2026 net pricing expected to remain stable with current Medicare contracts influencing high gross-to-net (GTN) guidance [12] - **Strategic Interest:** - Potential for M&A activity as companies like ORIC attract interest due to their prostate cancer programs [43] Conclusion - The biotechnology sector is poised for significant developments in 2026, with multiple companies presenting strong investment opportunities based on upcoming catalysts, drug launches, and strategic positioning in the market.

Core Insights - Jefferies has released a report on the outlook for the U.S. biotech industry in 2026, highlighting key clinical trial data disclosures, new drug approvals, and policy dynamics that could lead to value re-evaluation for companies in the sector [1] Six Preferred Stocks - Jefferies identified six companies as core recommendations for 2026 based on market catalysts and valuation potential: - Dianthus Therapeutics (DNTH.US), target price $66: Focused on claseprubart for various neuromuscular diseases, with peak revenue estimated at $2 billion [2] - Taysha Gene Therapies (TSHA.US), target price $11: TSHA-102 for Rett syndrome, with peak revenue potential of $2 billion and a key trial data disclosure expected by the end of 2026 [2] - Tyra Biosciences (TYRA.US), target price $32: Dabogratinib for bladder cancer and achondroplasia, with critical data expected next year [3] - Tango Therapeutics (TNGX.US), target price $14: Collaboration with Revolution Medicines for a pancreatic cancer treatment, with data expected in mid-2026 [3] - ORIC Pharmaceuticals (ORIC.US), target price $23: Two potential assets targeting prostate cancer and lung cancer, with key data expected next year [4] - Solid Biosciences (SLDB.US), target price $15: Focused on gene therapy for Duchenne muscular dystrophy, with critical meetings with the FDA planned for 2026 [4] Seven Undervalued Companies - The report also highlighted seven undervalued companies with significant catalysts: - Ultragenyx Pharmaceutical (RARE.US), target price $114: Expected key catalysts in 2026, including data for treatments for osteogenesis imperfecta and Angelman syndrome [5] - Beam Therapeutics (BEAM.US), target price $41: Updates on AATD therapy and SCD therapy expected in 2026, showcasing strong potential [5] - Aurinia Pharmaceuticals (AUPH.US), target price $21: Steady growth in lupus nephritis treatment, with new drug development paths expected to expand growth [6] - Kodiak Sciences (KOD.US), target price $39: Anticipated data from three pivotal trials in 2026, with significant potential for stock volatility [7] - Intellia Therapeutics (NTLA.US), target price $45: Key data for hereditary angioedema therapy expected in mid-2026, with sufficient cash reserves to support operations [7] - Compass Therapeutics (CMPX.US), target price $8: Data for cholangiocarcinoma therapy expected in early 2026, with a significant market opportunity [8] - KalVista Pharmaceuticals (KALV.US), target price $38: First oral treatment for hereditary angioedema expected to see rapid growth in 2026 [8] Five Potential Acquisition Targets - Jefferies identified five companies that may become acquisition targets in 2026 due to their unique assets or market positions: - Arrowhead Pharmaceuticals (ARWR.US): Strong RNAi product line for cardiovascular and metabolic diseases [9] - Celcuity (CELC.US): Unique efficacy of gedatolisib in breast cancer [9] - ORIC Pharmaceuticals: High-value prostate and lung cancer projects [9] - Travere Therapeutics (TVTX.US): Potential for significant market expansion in rare kidney diseases [9] - KalVista Pharmaceuticals: First-mover advantage in oral HAE treatment [9]